Patent ID: 8741837

Claim:
A method for inhibiting HCV protease, or a mutant thereof, in a patient comprising the step of administering to a patient in need thereof a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: R 1 and R 1′ are independently hydrogen or optionally substituted C 1-6 aliphatic, or R 1 and R 1′ are taken together to form an optionally substituted 3-7 membered carbocyclic ring; R 2a is —OH or —NHSO 7 R 2 ; R 2 is —N(R) 2 or an optionally substituted group selected from C 3-7 cycloalkyl, a bridged bicyclic, 6-10 membered aryl, 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 4-7 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each R is independently hydrogen, optionally substituted C 1-6 aliphatic, or: two R on the same nitrogen atom are taken together with the nitrogen to form a 4-7 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R 3 is selected from the group consisting of: R 4 is H, —NHC(O)R 5 , —NHC(O)OR 6 , or a natural or unnatural amino acid side-chain group; each R 5 is independently —N(R) 2 or an optionally substituted group selected from C 1-6 aliphatic, a bridged bicyclic, 6-10 membered aryl, 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 4-7 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R 6 is an optionally substituted group selected from C 1-6 aliphatic, a bridged bicyclic, 6-10 membered aryl, 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 4-7 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and R 7 is an optionally substituted group selected from C 1-6 aliphatic, a bridged bicyclic, 6-10 membered aryl, 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 4-7 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and R z is or R 4 and R z are taken together with their intervening atoms to form an optionally substituted, saturated or unsaturated 16-22 membered ring having 2-6 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each occurrence of R y is independently selected from halogen, —OR ∘ , —CN, —NO 2 , —N(R ∘ ) 2 , or optionally substituted C 1-4 aliphatic; R ∘ is an optionally substituted group selected from C 1-6 aliphatic; m is an integer from 0 to 4, inclusive; s is an integer from 0 to 4, inclusive; t is an integer from 0 to 4, inclusive; wherein the sum of s and t is non-zero.